BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sahasrabuddhe VV, Gunja MZ, Graubard BI, Trabert B, Schwartz LM, Park Y, Hollenbeck AR, Freedman ND, McGlynn KA. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst. 2012;104:1808-1814. [PMID: 23197492 DOI: 10.1093/jnci/djs452] [Cited by in Crossref: 131] [Cited by in F6Publishing: 120] [Article Influence: 13.1] [Reference Citation Analysis]
Number Citing Articles
1 Kamaraju S, Drope J, Sankaranarayanan R, Shastri S. Cancer Prevention in Low-Resource Countries: An Overview of the Opportunity. Am Soc Clin Oncol Educ Book 2020;40:1-12. [PMID: 32239989 DOI: 10.1200/EDBK_280625] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Roehlen N, Baumert TF. Uncovering the mechanism of action of aspirin in HCC chemoprevention. EBioMedicine 2019;46:21-2. [PMID: 31399384 DOI: 10.1016/j.ebiom.2019.07.047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Singh P, Singh S. Re: nonsteroidal antiinflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst 2013;105:666-7. [PMID: 23591463 DOI: 10.1093/jnci/djt062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
4 Kashfi K, Chattopadhyay M, Kodela R. NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties. Redox Biol 2015;6:287-96. [PMID: 26298203 DOI: 10.1016/j.redox.2015.08.012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
5 Carrat F. Statin and aspirin for prevention of hepatocellular carcinoma: what are the levels of evidence? Clin Res Hepatol Gastroenterol 2014;38:9-11. [PMID: 24183917 DOI: 10.1016/j.clinre.2013.09.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
6 Aiolfi R, Sitia G. Chronic hepatitis B: role of anti-platelet therapy in inflammation control. Cell Mol Immunol 2015;12:264-8. [PMID: 25578311 DOI: 10.1038/cmi.2014.124] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
7 McGlynn KA, Divine GW, Sahasrabuddhe VV, Engel LS, VanSlooten A, Wells K, Yood MU, Alford SH. Statin use and risk of hepatocellular carcinoma in a U.S. population. Cancer Epidemiol. 2014;38:523-527. [PMID: 25113938 DOI: 10.1016/j.canep.2014.06.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
8 Lee TY, Hsu YC, Tseng HC, Lin JT, Wu MS, Wu CY. Association of Daily Aspirin Therapy With Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis C Virus Infection. Clin Gastroenterol Hepatol 2020;18:2784-2792.e7. [PMID: 32360983 DOI: 10.1016/j.cgh.2020.04.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
9 Bahde R, Kapoor S, Gupta S. Nonselective inhibition of prostaglandin-endoperoxide synthases by naproxen ameliorates acute or chronic liver injury in animals. Exp Mol Pathol 2014;96:27-35. [PMID: 24220607 DOI: 10.1016/j.yexmp.2013.10.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
10 Oei RW, Ye L, Kong F, Du C, Zhai R, Xu T, Shen C, Wang X, He X, Kong L, Hu C, Ying H. Prognostic value of inflammation-based prognostic index in patients with nasopharyngeal carcinoma: a propensity score matching study. Cancer Manag Res 2018;10:2785-97. [PMID: 30147375 DOI: 10.2147/CMAR.S171239] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
11 Tao Y, Li Y, Liu X, Deng Q, Yu Y, Yang Z. Nonsteroidal anti-inflammatory drugs, especially aspirin, are linked to lower risk and better survival of hepatocellular carcinoma: a meta-analysis. Cancer Manag Res 2018;10:2695-709. [PMID: 30147368 DOI: 10.2147/CMAR.S167560] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
12 Lee PC, Yeh CM, Hu YW, Chen CC, Liu CJ, Su CW, Huo TI, Huang YH, Chao Y, Chen TJ, Lin HC, Wu JC. Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. Ann Surg Oncol 2016;23:874-83. [PMID: 27541812 DOI: 10.1245/s10434-016-5520-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
13 Orman ES, Hayashi PH. Re: nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst 2013;105:667. [PMID: 23591462 DOI: 10.1093/jnci/djt061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Shin S, Lee SH, Lee M, Kim JH, Lee W, Lee HW, Park MS, Park S, Kim TS, Choi DH. Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis. Medicine (Baltimore) 2020;99:e19008. [PMID: 32118712 DOI: 10.1097/MD.0000000000019008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Klein S, Dufour JF. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Hepat Oncol 2017;4:83-98. [PMID: 30191057 DOI: 10.2217/hep-2017-0013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
16 Sun J, Tao R, Mao T, Feng Z, Guo Q, Zhang X. The involvement of lipid raft pathway in suppression of TGFβ-mediated metastasis by tolfenamic acid in hepatocellular carcinoma cells. Toxicol Appl Pharmacol 2019;380:114696. [PMID: 31381904 DOI: 10.1016/j.taap.2019.114696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Cheema E, Al-Aryan A, Al-Hamid A. Medicine use and medicine-related problems in patients with liver cirrhosis: a systematic review of quantitative and qualitative studies. Eur J Clin Pharmacol 2019;75:1047-58. [PMID: 31079169 DOI: 10.1007/s00228-019-02688-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
18 Chen W, Wang JB, Abnet CC, Dawsey SM, Fan JH, Yin LY, Yin J, Taylor PR, Qiao YL, Freedman ND. Association between C-reactive protein, incident liver cancer, and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2015;24:386-92. [PMID: 25613115 DOI: 10.1158/1055-9965.EPI-14-1038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
19 Kim G, Jang SY, Nam CM, Kang ES. Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study. J Hepatol. 2018;68:476-484. [PMID: 29107150 DOI: 10.1016/j.jhep.2017.10.018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
20 Li WQ, Park Y, McGlynn KA, Hollenbeck AR, Taylor PR, Goldstein AM, Freedman ND. Index-based dietary patterns and risk of incident hepatocellular carcinoma and mortality from chronic liver disease in a prospective study. Hepatology 2014;60:588-97. [PMID: 24715615 DOI: 10.1002/hep.27160] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
21 Du ZQ, Zhao JZ, Dong J, Bi JB, Ren YF, Zhang J, Khalid B, Wu Z, Lv Y, Zhang XF, Wu RQ. Effect of low-dose aspirin administration on long-term survival of cirrhotic patients after splenectomy: A retrospective single-center study. World J Gastroenterol 2019; 25(28): 3798-3807 [PMID: 31391774 DOI: 10.3748/wjg.v25.i28.3798] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
22 Simon TG, Chan AT. Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma. Clin Liver Dis 2020;24:549-76. [PMID: 33012445 DOI: 10.1016/j.cld.2020.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BM, Poen AC, van Nieuwkerk KM, Drenth JP, Witteman BJ, Tuynman HA, Naber AH, Kingma PJ, van Buuren HR, van Hoek B, Vleggaar FP, van Geloven N, Beuers U, Ponsioen CY; on behalf of the EpiPSCPBC Study Group. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis: Boonstra et al. Hepatology 2013;58:2045-55. [DOI: 10.1002/hep.26565] [Cited by in Crossref: 335] [Cited by in F6Publishing: 283] [Article Influence: 37.2] [Reference Citation Analysis]
24 Simon TG, Duberg AS, Aleman S, Chung RT, Chan AT, Ludvigsson JF. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. N Engl J Med 2020;382:1018-28. [PMID: 32160663 DOI: 10.1056/NEJMoa1912035] [Cited by in Crossref: 54] [Cited by in F6Publishing: 22] [Article Influence: 27.0] [Reference Citation Analysis]
25 Lu L, Sun HC, Zhang W, Chai ZT, Zhu XD, Kong LQ, Wang WQ, Zhang KZ, Zhang YY, Zhang QB, Ao JY, Li JQ, Wang L, Wu WZ, Tang ZY. Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. PLoS One 2013;8:e65023. [PMID: 23741443 DOI: 10.1371/journal.pone.0065023] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
26 Lu T, Seto WK, Zhu RX, Lai CL, Yuen MF. Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. World J Gastroenterol 2013; 19(47): 8887-8894 [PMID: 24379612 DOI: 10.3748/wjg.v19.i47.8887] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
27 Zhang X, Guan L, Tian H, Zeng Z, Chen J, Huang D, Sun J, Guo J, Cui H, Li Y. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. Front Oncol 2021;11:686962. [PMID: 34568017 DOI: 10.3389/fonc.2021.686962] [Reference Citation Analysis]
28 Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population: THE USE OF ASPIRIN AND NSAIDS IN THE U.S. POPULATION. Pharmacoepidemiol Drug Saf 2014;23:43-50. [DOI: 10.1002/pds.3463] [Cited by in Crossref: 164] [Cited by in F6Publishing: 148] [Article Influence: 18.2] [Reference Citation Analysis]
29 Singh S, Singh PP, Roberts LR, Sanchez W. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2014;11:45-54. [PMID: 23938452 DOI: 10.1038/nrgastro.2013.143] [Cited by in Crossref: 185] [Cited by in F6Publishing: 168] [Article Influence: 20.6] [Reference Citation Analysis]
30 Goossens N, Hoshida Y. Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases? Gastroenterology 2016;150:1710-7. [PMID: 26784140 DOI: 10.1053/j.gastro.2016.01.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
31 Scheiner B, Kirstein M, Popp S, Hucke F, Bota S, Rohr-Udilova N, Reiberger T, Müller C, Trauner M, Peck-Radosavljevic M, Vogel A, Sieghart W, Pinter M. Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. Liver Cancer 2019;8:203-17. [PMID: 31192156 DOI: 10.1159/000489833] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
32 Boas FE, Ziv E, Yarmohammadi H, Brown KT, Erinjeri JP, Sofocleous CT, Harding JJ, Solomon SB. Reply to: "Adjuvant Medications that Improve Survival after Locoregional Therapy". J Vasc Interv Radiol 2017;28:1335-6. [PMID: 28841960 DOI: 10.1016/j.jvir.2017.06.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Muhimpundu S, Conway RBN, Warren Andersen S, Lipworth L, Steinwandel MD, Blot WJ, Shu XO, Sudenga SL. Racial Differences in Hepatocellular Carcinoma Incidence and Risk Factors among a Low Socioeconomic Population. Cancers (Basel) 2021;13:3710. [PMID: 34359611 DOI: 10.3390/cancers13153710] [Reference Citation Analysis]
34 McGlynn KA, Hagberg K, Chen J, Braunlin M, Graubard BI, Suneja N, Jick S, Sahasrabuddhe VV. Menopausal hormone therapy use and risk of primary liver cancer in the clinical practice research datalink. Int J Cancer 2016;138:2146-53. [PMID: 26662112 DOI: 10.1002/ijc.29960] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
35 Fan SH, Wang YY, Lu J, Zheng YL, Wu DM, Li MQ, Hu B, Zhang ZF, Cheng W, Shan Q. Luteoloside suppresses proliferation and metastasis of hepatocellular carcinoma cells by inhibition of NLRP3 inflammasome. PLoS One 2014;9:e89961. [PMID: 24587153 DOI: 10.1371/journal.pone.0089961] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 7.0] [Reference Citation Analysis]
36 Sitia G, Iannacone M, Guidotti LG. Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatol. 2013;59:1135-1138. [PMID: 23742914 DOI: 10.1016/j.jhep.2013.05.040] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 5.6] [Reference Citation Analysis]
37 Ollivier-Hourmand I, Nguyen N, De Gottardi A, Valla D, Hillaire S, Dutheil D, Bureau C, Hernandez-Gea V, De Raucourt E, Plessier A. Management of anticoagulation in adult patients with chronic parenchymal or vascular liver disease: Vascular liver diseases: Position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver. Clin Res Hepatol Gastroenterol 2020;44:438-46. [PMID: 32278777 DOI: 10.1016/j.clinre.2020.03.006] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Shen Y, Risch H, Lu L, Ma X, Irwin ML, Lim JK, Taddei T, Pawlish K, Stroup A, Brown R, Wang Z, Jia W, Wong L, Mayne ST, Yu H. Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case-control study. Cancer Causes Control 2020;31:321-32. [PMID: 32060838 DOI: 10.1007/s10552-020-01277-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
39 Zhou Y, Peng H, Liu Z, Zhang KK, Jendrusch C, Drake M, Hao Y, Xie L. Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero. Lab Invest 2019;99:244-59. [PMID: 30413815 DOI: 10.1038/s41374-018-0144-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
40 Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol 2018;2:6. [PMID: 29872724 DOI: 10.1038/s41698-018-0048-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 18.8] [Reference Citation Analysis]
41 Deng X, Zhao Z, Xiong S, Xiong R, Liu J, Wang Z, Zou L, Lei X, Cao X, Xie Z, Chen Y, Zheng X, Liu Y, Tang G. Synthesis and evaluation of antitumour activity in vitro and in vivo of chrysin salicylate derivatives. Natural Product Research 2018;32:2178-86. [DOI: 10.1080/14786419.2017.1371159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
42 Gao M, Kong Q, Hua H, Yin Y, Wang J, Luo T, Jiang Y. AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin. Oncotarget 2016;7:16349-61. [PMID: 26918349 DOI: 10.18632/oncotarget.7648] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
43 Lichtenberger LM, Fang D, Bick RJ, Poindexter BJ, Phan T, Bergeron AL, Pradhan S, Dial EJ, Vijayan KV. Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1. Cancer Prev Res (Phila) 2017;10:142-52. [PMID: 27998883 DOI: 10.1158/1940-6207.CAPR-16-0241] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
44 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
45 Davis JPE, Caldwell SH. Healing gone wrong: convergence of hemostatic pathways and liver fibrosis? Clin Sci (Lond) 2020;134:2189-201. [PMID: 32844997 DOI: 10.1042/CS20191102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Ballerini P, Contursi A, Bruno A, Mucci M, Tacconelli S, Patrignani P. Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies. Front Pharmacol 2022;13:838079. [DOI: 10.3389/fphar.2022.838079] [Reference Citation Analysis]
47 Banerjee I, Fisher PB, Sarkar D. Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC). Adv Cancer Res 2021;152:329-81. [PMID: 34353442 DOI: 10.1016/bs.acr.2021.05.003] [Reference Citation Analysis]
48 Sitia G. Platelets Promote Liver Immunopathology Contributing to Hepatitis B Virus–Mediated Hepatocarcinogenesis. Seminars in Oncology 2014;41:402-5. [DOI: 10.1053/j.seminoncol.2014.04.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
49 Tan RZH, Lockart I, Abdel Shaheed C, Danta M. Systematic review with meta-analysis: The effects of non-steroidal anti-inflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma. Aliment Pharmacol Ther 2021;54:356-67. [PMID: 34247393 DOI: 10.1111/apt.16515] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Vad NM, Kudugunti SK, Wang H, Bhat GJ, Moridani MY. Efficacy of acetylsalicylic acid (aspirin) in skin B16-F0 melanoma tumor-bearing C57BL/6 mice. Tumor Biol 2014;35:4967-76. [DOI: 10.1007/s13277-014-1654-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
51 Wang S, Yu Y, Ryan PM, Dang M, Clark C, Kontogiannis V, Rahmani J, Varkaneh HK, Salehisahlabadi A, Day AS, Zhang Y. Association of aspirin therapy with risk of hepatocellular carcinoma: A systematic review and dose-response analysis of cohort studies with 2.5 million participants. Pharmacol Res 2020;151:104585. [PMID: 31816436 DOI: 10.1016/j.phrs.2019.104585] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
52 Ricciotti E, Wangensteen KJ, FitzGerald GA. Aspirin in Hepatocellular Carcinoma. Cancer Res 2021;81:3751-61. [PMID: 33893087 DOI: 10.1158/0008-5472.CAN-21-0758] [Reference Citation Analysis]
53 Czajka P, Przybyłkowski A, Nowak A, Postula M, Wolska M, Mirowska-Guzel D, Czlonkowska A, Eyileten C. Antiplatelet drugs and liver fibrosis. Platelets 2021;:1-10. [PMID: 33577391 DOI: 10.1080/09537104.2021.1883574] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
54 Wang M, Li N, Ai L, Li L, Chen X, Jia Y, Wang X. Poly[(2-(acryloyloxy) ethyl]trimethylammonium chloride- co -ethylene dimethacrylate monolith on-line solid-phase extraction coupled with liquid chromatography and tandem mass spectrometry for the fast determination of salicylic acid in foodstuffs. J Sep Sci 2018;41:3432-40. [DOI: 10.1002/jssc.201800464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
55 Miyashita T, Tajima H, Makino I, Nakagawara H, Kitagawa H, Fushida S, Harmon JW, Ohta T. Metastasis-promoting role of extravasated platelet activation in tumor. Journal of Surgical Research 2015;193:289-94. [DOI: 10.1016/j.jss.2014.07.037] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
56 Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol. 2014;61:S79-S90. [PMID: 25443348 DOI: 10.1016/j.jhep.2014.07.010] [Cited by in Crossref: 124] [Cited by in F6Publishing: 110] [Article Influence: 15.5] [Reference Citation Analysis]
57 Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, Tanabe KK. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. J Clin Med 2020;9:E3817. [PMID: 33255794 DOI: 10.3390/jcm9123817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
58 Xue M, Lin X, Lin QX, Pu X, Liu J, Li XF, Hou J, Liu X, Chen R. Association between hepatitis B and E virus infection and hepatocellular carcinoma risk. Int J Cancer 2021;148:2974-81. [PMID: 33554326 DOI: 10.1002/ijc.33505] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Shebl FM, Hsing AW, Park Y, Hollenbeck AR, Chu LW, Meyer TE, Koshiol J. Non-steroidal anti-inflammatory drugs use is associated with reduced risk of inflammation-associated cancers: NIH-AARP study. PLoS One 2014;9:e114633. [PMID: 25551641 DOI: 10.1371/journal.pone.0114633] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
60 Alfonso L, Ai G, Spitale RC, Bhat GJ. Molecular targets of aspirin and cancer prevention. Br J Cancer. 2014;111:61-67. [PMID: 24874482 DOI: 10.1038/bjc.2014.271] [Cited by in Crossref: 118] [Cited by in F6Publishing: 97] [Article Influence: 14.8] [Reference Citation Analysis]
61 Aleksandrova K, Boeing H, Nöthlings U, Jenab M, Fedirko V, Kaaks R, Lukanova A, Trichopoulou A, Trichopoulos D, Boffetta P. Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. Hepatology. 2014;60:858-871. [PMID: 24443059 DOI: 10.1002/hep.27016] [Cited by in Crossref: 112] [Cited by in F6Publishing: 115] [Article Influence: 14.0] [Reference Citation Analysis]
62 Yeh CC, Lin JT, Jeng LB, Ho HJ, Yang HR, Wu MS, Kuo KN, Wu CY. Nonsteroidal anti-inflammatory drugs are associated with reduced risk of early hepatocellular carcinoma recurrence after curative liver resection: a nationwide cohort study. Ann Surg 2015;261:521-6. [PMID: 24950265 DOI: 10.1097/SLA.0000000000000746] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
63 Sahin IH, Hassan MM, Garrett CR. Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers: current state-of-the science. Cancer Lett. 2014;345:249-257. [PMID: 24021750 DOI: 10.1016/j.canlet.2013.09.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
64 Hanna D, Sugamori KS, Bott D, Grant DM. The impact of sex on hepatotoxic, inflammatory and proliferative responses in mouse models of liver carcinogenesis. Toxicology 2020;442:152546. [PMID: 32763287 DOI: 10.1016/j.tox.2020.152546] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Iannacone M. Platelet-mediated modulation of adaptive immunity. Semin Immunol 2016;28:555-60. [PMID: 27802906 DOI: 10.1016/j.smim.2016.10.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
66 Ai G, Dachineni R, Muley P, Tummala H, Bhat GJ. Aspirin and salicylic acid decrease c-Myc expression in cancer cells: a potential role in chemoprevention. Tumour Biol. 2016;37:1727-1738. [PMID: 26314861 DOI: 10.1007/s13277-015-3959-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
67 Li Z, Wang Z, Shen B, Chen C, Ding X, Song H. Effects of aspirin on the gastrointestinal tract: Pros vs. cons. Oncol Lett 2020;20:2567-78. [PMID: 32782574 DOI: 10.3892/ol.2020.11817] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Koh WP, Dan YY, Goh GB, Jin A, Wang R, Yuan JM. Dietary fatty acids and risk of hepatocellular carcinoma in the Singapore Chinese health study. Liver Int 2016;36:893-901. [PMID: 26443688 DOI: 10.1111/liv.12978] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
69 Küçükgüzel ŞG, Koç D, Çıkla-Süzgün P, Özsavcı D, Bingöl-Özakpınar Ö, Mega-Tiber P, Orun O, Erzincan P, Sağ-Erdem S, Şahin F. Synthesis of Tolmetin Hydrazide-Hydrazones and Discovery of a Potent Apoptosis Inducer in Colon Cancer Cells. Arch Pharm (Weinheim) 2015;348:730-42. [PMID: 26287512 DOI: 10.1002/ardp.201500178] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
70 Yang B, Petrick JL, Chen J, Hagberg KW, Sahasrabuddhe VV, Graubard BI, Jick S, McGlynn KA. Associations of NSAID and paracetamol use with risk of primary liver cancer in the Clinical Practice Research Datalink. Cancer Epidemiol 2016;43:105-11. [PMID: 27420633 DOI: 10.1016/j.canep.2016.06.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
71 Schon HT, Weiskirchen R. Exercise-Induced Release of Pharmacologically Active Substances and Their Relevance for Therapy of Hepatic Injury. Front Pharmacol 2016;7:283. [PMID: 27625607 DOI: 10.3389/fphar.2016.00283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
72 Li H, Song P, Zou B, Liu M, Cui K, Zhou P, Li S, Zhang B. Circulating Tumor Cell Analyses in Patients With Esophageal Squamous Cell Carcinoma Using Epithelial Marker-Dependent and -Independent Approaches. Medicine (Baltimore). 2015;94:e1565. [PMID: 26402816 DOI: 10.1097/md.0000000000001565] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
73 Liu Z, Zhang A, Zheng L, Johnathan AF, Zhang J, Zhang G. The Biological Significance and Regulatory Mechanism of c-Myc Binding Protein 1 (MBP-1). Int J Mol Sci 2018;19:E3868. [PMID: 30518090 DOI: 10.3390/ijms19123868] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
74 Memel ZN, Arvind A, Moninuola O, Philpotts L, Chung RT, Corey KE, Simon TG. Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Hepatol Commun 2021;5:133-43. [PMID: 33437907 DOI: 10.1002/hep4.1640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
75 Hua H, Zhang H, Kong Q, Wang J, Jiang Y. Complex roles of the old drug aspirin in cancer chemoprevention and therapy. Med Res Rev 2019;39:114-45. [PMID: 29855050 DOI: 10.1002/med.21514] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
76 Boas FE, Ziv E, Yarmohammadi H, Brown KT, Erinjeri JP, Sofocleous CT, Harding JJ, Solomon SB. Adjuvant Medications That Improve Survival after Locoregional Therapy. J Vasc Interv Radiol 2017;28:971-977.e4. [PMID: 28527884 DOI: 10.1016/j.jvir.2017.04.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
77 Kim AK, Dziura J, Strazzabosco M. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma: the egg of columbus or another illusion? Hepatology 2013;58:819-21. [PMID: 23703812 DOI: 10.1002/hep.26498] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
78 Boas FE, Brown KT, Ziv E, Yarmohammadi H, Sofocleous CT, Erinjeri JP, Harding JJ, Solomon SB. Aspirin Is Associated With Improved Liver Function After Embolization of Hepatocellular Carcinoma. AJR Am J Roentgenol 2019;213:1-7. [PMID: 31120783 DOI: 10.2214/AJR.18.20846] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
79 Yuan JM, Grouls M, Carmella SG, Wang R, Heskin A, Jiang Y, Tan YT, Adams-Haduch J, Gao YT, Hecht SS. Prediagnostic levels of urinary 8-epi-prostaglandin F2α and prostaglandin E2 metabolite, biomarkers of oxidative damage and inflammation, and risk of hepatocellular carcinoma. Carcinogenesis 2019;40:989-97. [PMID: 30615102 DOI: 10.1093/carcin/bgy180] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
80 Johnson PJ. How Do Mechanisms of Hepatocarcinogenesis (HBV, HCV, and NASH) Affect Our Understanding and Approach to HCC? American Society of Clinical Oncology Educational Book 2013. [DOI: 10.14694/edbook_am.2013.33.e132] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
81 McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 2015;19:223-38. [PMID: 25921660 DOI: 10.1016/j.cld.2015.01.001] [Cited by in Crossref: 365] [Cited by in F6Publishing: 347] [Article Influence: 52.1] [Reference Citation Analysis]
82 Zhang J, Zhang Q, Lou Y, Fu Q, Chen Q, Wei T, Yang J, Tang J, Wang J, Chen Y, Zhang X, Zhang J, Bai X, Liang T. Hypoxia-inducible factor-1α/interleukin-1β signaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment. Hepatology 2018;67:1872-89. [PMID: 29171040 DOI: 10.1002/hep.29681] [Cited by in Crossref: 84] [Cited by in F6Publishing: 93] [Article Influence: 21.0] [Reference Citation Analysis]
83 Abdelmonsif DA, Sultan AS, El-hadidy WF, Abdallah DM. Targeting AMPK, mTOR and β-Catenin by Combined Metformin and Aspirin Therapy in HCC: An Appraisal in Egyptian HCC Patients. Mol Diagn Ther 2018;22:115-27. [DOI: 10.1007/s40291-017-0307-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
84 Fox RK, Taddei TH, Kaplan DE. Aspirin Use and Risk of Hepatocellular Carcinoma in Hepatitis B. JAMA Intern Med 2019;179:640-1. [PMID: 30882884 DOI: 10.1001/jamainternmed.2018.8314] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
85 Takahashi K, Nagai S, Safwan M, Liang C, Ohkohchi N. Thrombocytopenia after liver transplantation: Should we care? World J Gastroenterol 2018; 24(13): 1386-1397 [PMID: 29632420 DOI: 10.3748/wjg.v24.i13.1386] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
86 Abou-alfa GK, Jarnagin W, El Dika I, D'angelica M, Lowery M, Brown K, Ludwig E, Kemeny N, Covey A, Crane CH, Harding J, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1314-1341.e11. [DOI: 10.1016/b978-0-323-47674-4.00077-3] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 McGlynn KA, Hagberg K, Chen J, Graubard BI, London WT, Jick S, Sahasrabuddhe VV. Statin use and risk of primary liver cancer in the Clinical Practice Research Datalink. J Natl Cancer Inst. 2015;107. [PMID: 25722350 DOI: 10.1093/jnci/djv009] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
88 Benhammou JN, Lin J, Hussain SK, El-Kabany M. Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma. Hepatoma Res 2020;6:35. [PMID: 32685690 DOI: 10.20517/2394-5079.2020.16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
89 Wang C, He W, Yuan Y, Zhang Y, Li K, Zou R, Liao Y, Liu W, Yang Z, Zuo D, Qiu J, Zheng Y, Li B, Yuan Y. Comparison of the prognostic value of inflammation-based scores in early recurrent hepatocellular carcinoma after hepatectomy. Liver Int 2020;40:229-39. [PMID: 31652394 DOI: 10.1111/liv.14281] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
90 Cheng R, Liu YJ, Cui JW, Yang M, Liu XL, Li P, Wang Z, Zhu LZ, Lu SY, Zou L, Wu XQ, Li YX, Zhou Y, Fang ZY, Wei W. Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells. Oncotarget 2017;8:30252-64. [PMID: 28415819 DOI: 10.18632/oncotarget.16325] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
91 Aiolfi R, Sitia G. Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:183-6. [PMID: 27508186 DOI: 10.2147/JHC.S48763] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
92 Choi WM, Kim HJ, Jo AJ, Choi SH, Han S, Ko MJ, Lim YS. Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study. Liver Int 2021. [PMID: 34242482 DOI: 10.1111/liv.15011] [Reference Citation Analysis]
93 Guo H, Liu J, Ben Q, Qu Y, Li M, Wang Y, Chen W, Zhang J. The aspirin-induced long non-coding RNA OLA1P2 blocks phosphorylated STAT3 homodimer formation. Genome Biol 2016;17:24. [PMID: 26898989 DOI: 10.1186/s13059-016-0892-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 8.0] [Reference Citation Analysis]
94 Ye Y, Guo J, Xiao P, Ning J, Zhang R, Liu P, Yu W, Xu L, Zhao Y, Yu J. Macrophages-induced long noncoding RNA H19 up-regulation triggers and activates the miR-193b/MAPK1 axis and promotes cell aggressiveness in hepatocellular carcinoma. Cancer Lett 2020;469:310-22. [PMID: 31705929 DOI: 10.1016/j.canlet.2019.11.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 42] [Article Influence: 11.3] [Reference Citation Analysis]
95 Kyriakopoulos AM, Nagl M, Baliou S, Zoumpourlis V. Alleviating Promotion of Inflammation and Cancer Induced by Nonsteroidal Anti-Inflammatory Drugs. Int J Inflam 2017;2017:9632018. [PMID: 28573063 DOI: 10.1155/2017/9632018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
96 Biondo-Simões MLP, Pessini VCA, Ichi CA, Robes RR, Ioshii S. Acetylsalicylic acid (Aspirin®) and liver regeneration: experimental study in rats. Rev Col Bras Cir 2021;48:e20213164. [PMID: 34816883 DOI: 10.1590/0100-6991e-20213164] [Reference Citation Analysis]
97 Xia H, Hui KM. Emergence of aspirin as a promising chemopreventive and chemotherapeutic agent for liver cancer. Cell Death Dis 2017;8:e3112. [PMID: 29022914 DOI: 10.1038/cddis.2017.513] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
98 Flores Bautista MC, Cortés-arriagada D, Shakerzadeh E, Chigo Anota E. Acetylsalicylic acid interaction with Boron nitride nanostructures – A density functional analysis. Journal of Molecular Liquids 2022;355:118980. [DOI: 10.1016/j.molliq.2022.118980] [Reference Citation Analysis]
99 Ji J, Tang J, Deng L, Xie Y, Jiang R, Li G, Sun B. LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway. Oncotarget. 2015;6:42813-42824. [PMID: 26540343 DOI: 10.18632/oncotarget.5970] [Cited by in Crossref: 88] [Cited by in F6Publishing: 96] [Article Influence: 14.7] [Reference Citation Analysis]
100 Young S, Chau G, Lee I, Yeh Y, Chao Y, Huo T, Su C, Lin H, Hou M, Lee M, Huang Y. Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. Journal of the Formosan Medical Association 2020;119:218-29. [DOI: 10.1016/j.jfma.2019.04.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
101 Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol. 2021;18:223-238. [PMID: 33349658 DOI: 10.1038/s41575-020-00381-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 24.5] [Reference Citation Analysis]
102 Liu J, Xie B, Chen S, Jiang F, Meng W. Association study of two inflammation-related polymorphisms with susceptibility to hepatocellular carcinoma: a meta-analysis. BMC Med Genet 2014;15:92. [PMID: 25108400 DOI: 10.1186/s12881-014-0092-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
103 Simon TG, Ma Y, Ludvigsson JF, Chong DQ, Giovannucci EL, Fuchs CS, Meyerhardt JA, Corey KE, Chung RT, Zhang X, Chan AT. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncol 2018;4:1683-90. [PMID: 30286235 DOI: 10.1001/jamaoncol.2018.4154] [Cited by in Crossref: 81] [Cited by in F6Publishing: 72] [Article Influence: 27.0] [Reference Citation Analysis]
104 Ho CM, Lee CH, Lee MC, Zhang JF, Wang JY, Hu RH, Lee PH. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study. BMC Cancer. 2018;18:401. [PMID: 29631561 DOI: 10.1186/s12885-018-4292-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
105 Hwang IC, Chang J, Kim K, Park SM. Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults. Sci Rep 2018;8:4968. [PMID: 29563592 DOI: 10.1038/s41598-018-23343-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
106 Petrick JL, Sahasrabuddhe VV, Chan AT, Alavanja MC, Beane-Freeman LE, Buring JE, Chen J, Chong DQ, Freedman ND, Fuchs CS, Gaziano JM, Giovannucci E, Graubard BI, Hollenbeck AR, Hou L, Jacobs EJ, King LY, Koshiol J, Lee IM, Linet MS, Palmer JR, Purdue MP, Rosenberg L, Schairer C, Sesso HD, Sigurdson AJ, Wactawski-Wende J, Zeleniuch-Jacquotte A, Campbell PT, McGlynn KA. NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project. Cancer Prev Res (Phila) 2015;8:1156-62. [PMID: 26391917 DOI: 10.1158/1940-6207.CAPR-15-0126] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
107 Dachineni R, Ai G, Kumar DR, Sadhu SS, Tummala H, Bhat GJ. Cyclin A2 and CDK2 as Novel Targets of Aspirin and Salicylic Acid: A Potential Role in Cancer Prevention. Mol Cancer Res 2016;14:241-52. [PMID: 26685215 DOI: 10.1158/1541-7786.MCR-15-0360] [Cited by in Crossref: 46] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
108 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 718] [Article Influence: 230.0] [Reference Citation Analysis]
109 Wang T, Wu H, Xie L, Liu Z, Long W, Cheng L, Ding Y, Yu R. Simultaneous and interference-free determination of eleven non-steroidal anti-inflammatory drugs illegally added into Chinese patent drugs using chemometrics-assisted HPLC-DAD strategy. Sci China Chem 2018;61:739-49. [DOI: 10.1007/s11426-017-9210-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
110 Peng T, Zhu A, Zhou Y, Hu T, Yue Z, Chen D, Wang G, Kang J, Fan C, Chen Y, Jiang H. Development of a simple method for simultaneous determination of nine subclasses of non-steroidal anti-inflammatory drugs in milk and dairy products by ultra-performance liquid chromatography with tandem mass spectrometry. Journal of Chromatography B 2013;933:15-23. [DOI: 10.1016/j.jchromb.2013.06.025] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
111 Sharma U, Barwal TS, Murmu M, Acharya V, Pant N, Dey D, Vivek, Gautam A, Bazala S, Singh I, Azzouz F, Bishayee A, Jain A. Clinical potential of long non-coding RNA LINC01133 as a promising biomarker and therapeutic target in cancers. Biomark Med 2022. [PMID: 35195032 DOI: 10.2217/bmm-2021-0682] [Reference Citation Analysis]
112 Lee TY, Hsu YC, Tseng HC, Yu SH, Lin JT, Wu MS, Wu CY. Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. JAMA Intern Med 2019;179:633-40. [PMID: 30882847 DOI: 10.1001/jamainternmed.2018.8342] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 23.5] [Reference Citation Analysis]
113 Tang J, Zhuo H, Zhang X, Jiang R, Ji J, Deng L, Qian X, Zhang F, Sun B. A novel biomarker Linc00974 interacting with KRT19 promotes proliferation and metastasis in hepatocellular carcinoma. Cell Death Dis. 2014;5:e1549. [PMID: 25476897 DOI: 10.1038/cddis.2014.518] [Cited by in Crossref: 114] [Cited by in F6Publishing: 121] [Article Influence: 14.3] [Reference Citation Analysis]
114 Dioguardi Burgio M, Bruno O, Agnello F, Torrisi C, Vernuccio F, Cabibbo G, Soresi M, Petta S, Calamia M, Papia G, Gambino A, Ricceri V, Midiri M, Lagalla R, Brancatelli G. The cheating liver: imaging of focal steatosis and fatty sparing. Expert Rev Gastroenterol Hepatol. 2016;10:671-678. [PMID: 27027652 DOI: 10.1586/17474124.2016.1169919] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
115 Pang Q, Jin H, Qu K, Man Z, Wang Y, Yang S, Zhou L, Liu H. The effects of nonsteroidal anti-inflammatory drugs in the incident and recurrent risk of hepatocellular carcinoma: a meta-analysis. Onco Targets Ther 2017;10:4645-56. [PMID: 29033583 DOI: 10.2147/OTT.S143154] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
116 Kanda T, Yokosuka O, Omata M. Hepatitis C virus and hepatocellular carcinoma. Biology (Basel) 2013;2:304-16. [PMID: 24832662 DOI: 10.3390/biology2010304] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
117 Li S, Dai W, Mo W, Li J, Feng J, Wu L, Liu T, Yu Q, Xu S, Wang W, Lu X, Zhang Q, Chen K, Xia Y, Lu J, Zhou Y, Fan X, Xu L, Guo C. By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma. Int J Cancer 2017;141:2571-84. [PMID: 28857200 DOI: 10.1002/ijc.31022] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 7.8] [Reference Citation Analysis]
118 Xue TC, Jia QA, Ge NL, Chen Y, Zhang BH, Ye SL. Imbalance in systemic inflammation and immune response following transarterial chemoembolization potentially increases metastatic risk in huge hepatocellular carcinoma. Tumour Biol. 2015;36:8797-8803. [PMID: 26058874 DOI: 10.1007/s13277-015-3632-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
119 Lee M, Chung GE, Lee JH, Oh S, Nam JY, Chang Y, Cho H, Ahn H, Cho YY, Yoo JJ, Cho Y, Lee DH, Cho EJ, Yu SJ, Lee DH, Lee JM, Kim YJ, Yoon JH. Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. Hepatology 2017;66:1556-69. [PMID: 28617992 DOI: 10.1002/hep.29318] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 8.8] [Reference Citation Analysis]
120 Wang JP, Kao F, Wu C, Hung Y, Chao Y, Chou Y, Li C. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: A population-based cohort study: NAs Reduce Risk of HCC in Chronic Hepatitis B. Cancer 2015;121:1446-55. [DOI: 10.1002/cncr.29159] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
121 Bellucci PN, González Bagnes MF, Di Girolamo G, González CD. Potential Effects of Nonsteroidal Anti-Inflammatory Drugs in the Prevention and Treatment of Type 2 Diabetes Mellitus. Journal of Pharmacy Practice 2017;30:549-56. [DOI: 10.1177/0897190016649551] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
122 Dallio M, Sangineto M, Romeo M, Villani R, Romano AD, Loguercio C, Serviddio G, Federico A. Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression. Int J Mol Sci 2021;22:E436. [PMID: 33406763 DOI: 10.3390/ijms22010436] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
123 Lisman T, Luyendyk JP. Platelets as Modulators of Liver Diseases. Semin Thromb Hemost 2018;44:114-25. [PMID: 28898899 DOI: 10.1055/s-0037-1604091] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
124 Noij DP, van Der Linden PW. Spontaneous regression of hepatocellular carcinoma in a Caucasian male patient: A case report and review of the literature. Mol Clin Oncol 2017;6:225-8. [PMID: 28357099 DOI: 10.3892/mco.2016.1115] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
125 Zheng YF, Zhang XY, Bu YZ. LINC01133 aggravates the progression of hepatocellular carcinoma by activating the PI3K/AKT pathway. J Cell Biochem 2019;120:4172-9. [PMID: 30548306 DOI: 10.1002/jcb.27704] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
126 Stoiber D, Assinger A. Platelet-Leukocyte Interplay in Cancer Development and Progression. Cells 2020;9:E855. [PMID: 32244723 DOI: 10.3390/cells9040855] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
127 Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagle CM, Jordan SJ, Risch HA, Rossing MA, Doherty JA, Goodman MT, Lurie G, Kjær SK, Hogdall E, Jensen A, Cramer DW, Terry KL, Vitonis A, Bandera EV, Olson S, King MG, Chandran U, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pearce CL, Pike MC, Berchuck A, Schildkraut JM, Wentzensen N; Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer)., Ovarian Cancer Association Consortium. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst 2014;106:djt431. [PMID: 24503200 DOI: 10.1093/jnci/djt431] [Cited by in Crossref: 138] [Cited by in F6Publishing: 125] [Article Influence: 17.3] [Reference Citation Analysis]
128 Xin Y, Yang Y, Liu N, Chen Y, Wang Y, Zhang X, Li X, Zhou X. Prognostic significance of systemic immune-inflammation index-based nomogram for early stage hepatocellular carcinoma after radiofrequency ablation. J Gastrointest Oncol 2021;12:735-50. [PMID: 34012662 DOI: 10.21037/jgo-20-342] [Reference Citation Analysis]
129 Vilarinho S, Taddei T. Therapeutic strategies for hepatocellular carcinoma: new advances and challenges. Curr Treat Options Gastroenterol 2015;13:219-34. [PMID: 25791207 DOI: 10.1007/s11938-015-0049-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]